Yanli Xue

Discovery of the First Potent, Selective, and <i>In Vivo</i> Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of <i>TRIM37</i>-Amplified Breast Cancer

Yin Sun, Yanli Xue, Pengkun Sun et al. · Journal of Medicinal Chemistry · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacology +13

Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study

Yin Sun, Ruifeng Wang, Yu Sun et al. · European Journal of Medicinal Chemistry · 2022 · 24 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer

Yin Sun, Yu Sun, Lin Wang et al. · European Journal of Medicinal Chemistry · 2022 · 23 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia

Yin Sun, Yanli Xue, Hongbing Liu et al. · Journal of Medicinal Chemistry · 2023 · 15 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Yin Sun, Lin Wang, Yu Sun et al. · European Journal of Medicinal Chemistry · 2022 · 12 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14